Brokerage Firm Rating Update on Celgene Corporation (CELG)

Celgene Corporation (CELG) : 14 brokerage houses believe that Celgene Corporation (CELG) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Celgene Corporation (CELG). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 17 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.35.

Celgene Corporation (CELG) : 14 Wall Street analysts covering Celgene Corporation (CELG) believe that the average level the stock could reach for the short term is $141.79. The maximum price target given is $162 and the minimum target for short term is around $120, hence the standard deviation is calculated at $12.26.


For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, BTIG Research upgrades its outlook on Celgene Corporation (NASDAQ:CELG). The current rating of the shares is Buy, according to the research report released by the firm. Previously, the company had a rating of Neutral. The rating by the firm was issued on August 4, 2016.

Celgene Corporation (NASDAQ:CELG): The stock opened at $106.73 and touched an intraday high of $107.91 on Wednesday. During the day, the stock corrected to an intraday low of $106.3, however, the bulls stepped in and pushed the price higher to close in the green at $106.96 with a gain of 0.23% for the day. The total traded volume for the day was 3,095,699. The stock had closed at $106.71 in the previous trading session.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.